Business Context and Reporting Period
This Form 8-K Current Report was filed by Altimmune, Inc. on February 24, 2025. The filing primarily addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of two new directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel appointments and associated compensation arrangements.
Material Changes
The Board of Directors increased its size from eight to ten members. Two new directors were appointed:
- Teri Lawver: Former Executive Vice President and Chief Commercial Officer at Dexcom (2023–2024) and former Worldwide Vice President, Immunology at Johnson & Johnson (2017–2023).
- Jerome Durso: Former President and CEO of Intercept Pharmaceuticals (2021–2023) and former SVP, Chief Commercial Officer at Sanofi.
Compensation and Governance Details
Both new directors are non-employee directors compensated under the Company's Non-Employee Director Compensation Policy. Their compensation package includes:
- An initial option award to purchase 69,800 shares of common stock each under the 2017 Omnibus Incentive Plan.
- An annual cash retainer of $40,000 each.
- Indemnification agreements consistent with those of other directors.
No family relationships or material interest transactions requiring disclosure under Item 404(a) of Regulation S-K were identified for either appointee.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 139,600 new option grants on potential dilution.
- Review the Company's 2017 Omnibus Incentive Plan to understand vesting schedules and exercise terms for the new director options.
- Confirm the strategic rationale for appointing directors with specific commercial and immunology expertise given Altimmune's pipeline.
- Check subsequent filings for any changes to the Board's committee assignments for the new directors.